Thymosin β 4 is a ubiquitous 43 amino acid, 5 kDa polypeptide that is an important mediator of cell proliferation, migration, and differentiation. It is the most abundant member of the β-thymosin family in mammalian tissue and is regarded as the main G-actin sequestering peptide. Thymosin β 4 is angiogenic and can promote endothelial cell migration and adhesion, tubule formation, aortic ring sprouting, and angiogenesis. It also accelerates wound healing and reduces inflammation when applied in dermal wound-healing assays. Using naturally occurring thymosin β 4 , proteolytic fragments, and synthetic peptides, we find that a seven amino acid actin binding motif of thymosin β 4 is essential for its angiogenic activity. Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin β 4 and the actin-binding motif of the peptide display near-identical activity at ~50 nM, whereas peptides lacking any portion of the actin motif were inactive. Furthermore, adhesion to thymosin β 4 was blocked by this seven amino acid peptide demonstrating it as the major thymosin β 4 cell binding site on the molecule. The adhesion and sprouting activity of thymosin β 4 was inhibited with the addition of 5-50 nM soluble actin. These results demonstrate that the actin binding motif of thymosin β 4 is an essential site for its angiogenic activity.
ngiogenesis is the formation of new blood vessels from pre-existing vasculature (1) . This process is essential for tissue growth and wound repair (2) . Angiogenesis involves cell attachment, basement membrane degradation, cell migration, proliferation, and differentiation. Tumor growth and metastasis are also angiogenesis-dependent (2, 3) . These newly formed blood vessels within tumors give tumor cells access to the circulation resulting in their metastasis in other areas of the body.
Many compounds have been used in vitro in studying the steps of angiogenesis (4) . Thymosin β 4 , a 43 amino acid peptide, is the most abundant member of the β-thymosins, a family of highly conserved 5 kD peptides (6) . Thymosin β 4 was first isolated from calf thymus and was later found in a variety of tissues and cell types as well as in malignant cells (7) (8) (9) (10) (11) . By using cDNA subtractive cloning in an in vitro vessel-forming assay for angiogenesis, thymosin β 4 expression A was increased in human umbilical vein endothelial cells (HUVECs) that were plated on Matrigel compared with HUVECs plated on plastic (5).
Although its role was initially attributed to T cell differentiation (7) , it later was found that thymosin β 4 binds to G-actin in a 1:1 complex that prevents monomeric G-actin from polymerizing to filamentous F-actin but supplies a pool of actin monomers inside the cells (12, 13) . We and others identified thymosin β 4 as an angiogenic factor with activity during HUVEC differentiation in vitro and in vivo (5, (14) (15) (16) . The addition of 0.5-500.0 nM exogenous thymosin β 4 promotes endothelial cell migration and protease activity. It also promotes angiogenesis in vivo and ex vivo in the nanogram range (15, 16) . Thymosin β 4 promotes dermal wound repair in rats and in aged and diabetic mice (16, 17) . Corneal wound healing was also accelerated with microgram amounts of thymosin β 4 in rodent eye injury models (18, 19) . In both models, thymosin β 4 increased wound closure and decreased inflammation. Thymosin β 4 -increased angiogenesis was observed only in the dermal repair models and not in the eye wounds. Recently, it has been shown that thymosin β 4 serves as a specific (glutamyl)-substrate of tissue transglutaminase and is cross-linked to fibrin by factor XIIIa after release from thrombinactivated platelets (20, 21) The mechanism by which thymosin β 4 acts is unknown, and its cell surface receptor has not been identified. Using various proteolytic and synthetic peptides in in vitro and ex vivo assays, we here identify the actin binding motif of the thymosin β 4 peptide as the active site for angiogenesis. Furthermore, soluble actin blocked the adhesion and angiogenic activities of intact thymosin β 4 . 4 19-26 , and Tβ 4 13-19 . Naturally occurring β-thymosins, thymosin β 4 -sulfoxide, and proteolytic peptide fragments (Table 1, the seven peptides in the first group) were prepared as described previously (22, 23) . All peptides were dissolved in phosphate-buffered saline (PBS) and stored in aliquots at -70°C.
METHODS AND MATERIALS

Peptides and fragments
Cells
HUVECs were isolated and used at passages 2-5 (5). The cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA), supplemented with 20% bovine calf serum (Hyclone Laboratories, Logan, UT), 200 µg/ml of endothelial cell growth supplement (ECGS) (Collaborative Biomedical Products, Bedford, MA), 0.8 U/ml heparin sodium (Fisher Scientific, Pittsburgh, PA), penicillin/streptomycin (Invitrogen), 10 µg/ml gentamycin (Invitrogen), and 1% fungizone (Invitrogen, Carlsbad, CA).
Cell adhesion
To determine which ions are needed for HUVEC adhesion, laminin-1 peptide (25 ng in 50 µl) and one test concentration of Tβ 4 (100 ng in 50 µl) in 0.1 M carbonate buffer, pH 9.4, were bound to the bottom of U-bottom 96-well plates overnight at 4°C. Wells were then washed twice with PBS and blocked with 150 µl of 3% BSA in PBS (Sigma Chemical Co., St. Louis, MO) at room temperature for 30 min. Various doses of calcium, magnesium, and manganese were first tested to determine the optimal concentrations for cell adhesion. The wells were washed again and 50,000 HUVECs in 50 µl of serum-free medium that contained the indicated salts (1 mM Ca 2+ , 0.5 mM Mg 2+ , and 0.5 mM Mn 2+ ), individually or in combination, were added to each well. The HUVECs used in this study were serum-starved for 2 h prior to use. The plate was incubated for 45 min at 37°C. Cells that did not attach were gently removed with two PBS washes. The remaining cells were stained with 0.2% crystal violet in 20% methanol, washed in water to remove excess stain, dried overnight at 37°C, and lysed with 10% SDS for 10 min; the plate OD was read at 600 nm. (Molecular Devices precision microplate reader). Each condition was assayed in triplicate, and the assay was repeated three times. When the seven amino acid thymosin β 4 actin binding peptide was tested in competition assays, it was first mixed with the cells prior to addition to the wells.
Boyden chamber assay
HUVEC migration assays were conducted in a 48-well micro-chemotaxis chamber (Neuro Probe Inc., Cabin John, MD) as described previously (24) . Briefly, PVP-free polycarbonate membranes with 8 µm pores were coated with 50 µg/ml of rat tail collagen (BD Biosciences, Bedford, MA) in RPMI 1640 that contained 25 mM HEPES (Invitrogen) at 4°C overnight. The membranes were dried at least 1 h prior to use. HUVECs were serum-starved for 2 h, harvested by using Versene (Invitrogen), and resuspended in binding medium that contained RPMI 1640 with 1% BSA and 25 mM HEPES. The lower wells of the chamber were loaded with 1, 10, 100, and 1000 ng/ml of thymosin β 4 or peptide fragments that were diluted in binding medium. Basic fibroblast growth factor (bFGF; 200 ng/ml) was used as a positive control. Cells were added to the upper portion of the chamber at a concentration of 50,000 cells per well. The chambers were incubated at 37°C for 4 h. The filters were fixed and stained by using Diff-Quik (VWR, Bridgeport, NJ). The cells that successfully migrated through the pores of the membrane were manually quantitated by using a CK-2 Olympus microscope at 10´ magnification. Each condition was assayed in triplicate, and the assay was repeated twice.
Chick aortic arch assay
The aortic arch of 13-day-old chick embryos was removed and placed in RPMI (method obtained from Robert Auerbach, University of Wisconsin, Madison, WI). After removal of surrounding connective tissue, transverse sections of the arch were made (1 mm). The resulting aortic rings were carefully attached to the bottom of a 48-well plate, one ring per well, with 20-30 µl of Matrigel (Collaborative Biomedical Products). The rings were placed so that the lumen of each ring could be seen. More Matrigel was added onto the top of the rings to seal them in place. A 100 µl volume of human endothelial-SFM basal growth medium (Invitrogen) containing 1% penicillin streptomycin was added to each well. Thymosin β 4 , peptide fragments, and exogenous actin (Sigma Chemical Co.) were added to wells in serum-free medium, bringing the final volume of each well to 400 µl. ECGS (200 µg/ml) was used as a positive control. The plates were incubated for 24 h at 37°C. Rings were fixed and stained with Diff-Quik solution II. Sprouting was scored by a blinded observer by using 10X magnification on an Olympus microscope. Six wells were used for each condition tested, and each assay was done three times.
RESULTS
Actin-mediated HUVEC cell adhesion to thymosin β 4
We first determined the optimal cation requirements for HUVEC adhesion to thymosin β 4 to optimize cell adhesion. Calcium alone, calcium and magnesium, and calcium and manganese all stimulated HUVEC adhesion to laminin-1, which was used as the control substrate (Fig. 1) . In contrast, calcium or calcium plus magnesium were inactive with thymosin β 4 . Combinations of calcium and manganese or magnesium and manganese both could support thymosin β 4 -mediated cell adhesion. We therefore conclude that manganese is required for cell adhesion to thymosin β 4 and used it in all subsequent adhesion assays. The amount of manganese used is above physiological levels but did not affect cell viability.
Actin has been reported to be on the cell surface of endothelial cells and to be important in angiogenin-mediated angiogenesis (25, 26) . Because thymosin β 4 contains an actin-binding domain, we added actin to the cell adhesion assay and found that soluble actin blocked adhesion to thymosin β 4 (Table 2A) . As a control, soluble actin had no effect on laminin-1-mediated adhesion. These data demonstrate that actin can block thymosin β 4 -mediated adhesion and suggest that the actin binding site on thymosin β 4 is important in cell binding to thymosin β 4 .
Actin blocks aortic ring vessel sprouting in the presence of thymosin β 4
Thymosin β 4 has previously been shown to promote vessel sprouting from rat aorta and from pig coronary artery rings in a dose-dependent manner (15, 27) . We also find that thymosin β 4 , at similar concentrations as reported, can promote such sprouting by using an embryonic chick aortic ring model (Fig. 2) . Further, we find that actin has angiogenic activity in this model system (Table 2B) . Actin has been found to be angiogenic in the chick CAM assay (Y. S. Gho, unpublished). Neither thymosin β 4 nor actin were as active as the ECGS positive control in promoting sprouting. Thymosin β 4 -mediated sprouting was significantly blocked by the addition of exogenous actin (Table 2B ). The effect of exogenous actin on thymosin β 4 -mediated angiogenesis is specific because exogenous actin did not inhibit ECGS-mediated vessel sprouting. Some increase is observed in sprouting when actin and ECGS are added together. Both are angiogenic molecules and appear to act in an additive fashion in this assay. These data demonstrate that thymosin β 4 promotes angiogenesis ex vivo and that exogenous actin blocks this activity.
Identification of the actin binding domain on thymosin β 4 for its angiogenic activity
We next determined the active site on thymosin β 4 for endothelial cell migration and vessel sprouting by using various synthetic peptides and proteolytic fragments of thymosin β 4 . Both synthetic and naturally occurring thymosin β 4 were active in both assays (Figs. 2 ) were generally highly active in the assays. In contrast, synthetic peptides and proteolytic fragments lacking the actin binding sequence (Tβ 4 1-6 and Tβ 4 13-19 ) were inactive, with Tβ 4 1-15 showing very weak activity in only the sprouting assay. The smallest active synthetic peptide, Tβ 4 17-23 , contained seven amino acids and was fully active for migration and sprouting (Fig. 2, Table 1 ). All other members of the β-thymosins (β 4 -sulfoxide, β 4 Ala, β 9 , and β 10 ) with a conserved actin binding domain were also active ( Table 1 ). The actin binding domain of thymosin β 15 contained within amino acids 13-23 was active in the sprouting assay. These data demonstrate that the actin binding site contained within thymosin β 4 is active for angiogenesis. This peptide could also block cell adhesion to thymosin β 4 in a dose-dependent manner with 10 ng/ml inhibiting adhesion by 42% and 100 ng/ml inhibiting adhesion by 58%. The peptide did not block adhesion to laminin-1. Taken together with the actin competition data presented above, it is likely that thymosin β 4 binds to cell surface actin as a first step in angiogenesis. Related family members with sequence homology are also predicted to have this activity.
DISCUSSION
Thymosin β 4 has previously been found to promote angiogenesis (5, 13, 15, 16). Here we have localized the motif for this activity to the central actin binding domain by using seven different synthetic peptides and six different proteolytic fragments. Peptides and fragments containing the entire actin binding domain (LKKTETQ) were active for endothelial cell migration and vessel sprouting, whereas those lacking this sequence were inactive. A seven amino acid peptide, Tβ 4 
17-
(LKKTETQ)
, was the smallest peptide tested that could duplicate the activity of the intact molecule and block adhesion to thymosin β 4 . Actin has been shown to promote angiogenesis (Y. S. Gho and H. K. Kleinman, unpublished data), and it showed activity in our ex vivo vessel sprouting assay. When added together with thymosin β 4 , instead of further increasing sprouting activity, reduced activity was observed. It is likely that excess soluble actin bound to soluble thymosin β 4 and thus neutralized its activity. Exogenous actin also blocked cell adhesion to thymosin β 4 but not to laminin-1. These data suggest that thymosin β 4 interacts with endothelial cells to initiate angiogenesis via its central actin binding domain.
Actin is an abundant protein present in all cells. It is important in maintaining cell structure and regulating cell motility. Actin has previously been found to be an endothelial cell surface molecule that functions as a ligand for another adhesive, angiogenic molecule, angiogenin (25, 26) . Actin, however, has not been definitely demonstrated on the cell surface. Only one paper has shown evidence of this localization (25) , and more work needs to be done. The receptor for thymosin β 4 is not known, but thymosin β 4 binding and internalization have been demonstrated (27) . Similar to work described here, soluble exogenous actin blocked the angiogenic activity of angiogenin in the chick chorioallantoic membrane assay. Furthermore, antagonistic peptides that block the binding of angiogenin to actin inhibit its activity (28, 29) . Both thymosin β 4 and angiogenin increase protease activity (13, 30, 31) . Peptides antagonistic to the angiogenin receptor that block its binding to actin also block protease activity and tumor growth and metastasis in vivo (32, 33) .
Within the β-thymosin family, the actin binding motif is highly conserved (6) . Most of the heterogeneity of these molecules occurs at the carboxy terminus. Based on the conservation of the actin binding sequence, it was not surprising that the other members of the β-thymosin family tested were active for both endothelial cell migration and vessel sprouting. Thymosin β 15 is the only β-thymosin possessing an amino acid substitution within the expected actin binding domain, LKKTNT instead of LKKTET. Thymosin β 15 is increased in prostate cancer and is reported to be important in cell migration (34, 35) . It is possible that thymosin β 15 acts not only by increasing cell migration but also by increasing angiogenesis, which would contribute to the malignant potential of these tumor cells. Other investigators have shown that thymosin β 4 levels are elevated in metastatic lesions (36) (37) (38) and, when transfected into tumor cells, malignancy in vitro and in vivo is increased (39) . Furthermore, the sulfoxide of thymosin β 4 has been described to possess anti-inflammatory activity (40) . It likely acts in malignancy to increase migration, angiogenesis, and reduce immune surveillance. Table 1 Summary of studies performed with proteolytic and synthetic peptide fragments of thymosin β4.
The actin binding motif is underlined. The Boyden chamber migration assay was done by using HUVECs. In the chick aortic arch assay, endothelial cell sprouting was tested by using 13-day-old chick aortic arches. This assay was read within 48 h. Scoring of angiogenic activity in both assays was based on sprout density and length. Scoring of activity for each assay: n.t. = not tested, -= no activity, +/− = low activity, + = active, and ++ = high activity. The first seven components were prepared from the naturally occurring molecule as is the sulfoxide form, designated with (O). 17-23 , thymosin β 15 13-23 , and thymosin β 4 19-26 was tested using 13-day-old chick aortic arches. This assay was read within 48 h. Scoring of angiogenic activity was based on a scale of 0 to 6 units. Each score was based on sprout density and length. The negative control was subtracted form the samples shown. The mean of cell sprouting ± SD for each sample is shown. These studies were repeated three times, and six rings were used per test group.
